Tvardi Therapeutics
TVRD
156 hedge funds and large institutions have $494M invested in Tvardi Therapeutics in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 48 reducing their positions, and 25 closing their positions.
208% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $4.99M
16% more capital invested
Capital invested by funds: $425M → $494M (+$68.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.16% less ownership
Funds ownership: 1.98% → 1.82% (-0.16%)
4% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 48
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
3% less funds holding
Funds holding: 161 → 156 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$7.77M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$3.13M |
| 3 |
Millennium Management
New York
|
+$2.25M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.86M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$8.19M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$3.1M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.72M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.88M |
TVRD Hedge Fund Activity: Q4 2020 in Review
156 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2020, worth a combined $494M — up 16% from $425M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TVRD and 23 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 46 added.
The largest buyer was First Manhattan, adding an estimated $7.77M. The largest seller was T. Rowe Price Associates, cutting an estimated $10.9M.
- 156 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2020, down from 161 in Q3 2020.
- Funds reported $494M of Tvardi Therapeutics stock for Q4 2020, up 16% quarter-over-quarter.
- 23 funds opened new Tvardi Therapeutics positions in Q4 2020 and 25 closed out, a net change of -2 holders.
- The largest Tvardi Therapeutics buyer in Q4 2020 was First Manhattan, an estimated $7.77M added.
- The largest Tvardi Therapeutics seller in Q4 2020 was T. Rowe Price Associates, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2020.